The Experts below are selected from a list of 24 Experts worldwide ranked by ideXlab platform

Piero Ruggenenti - One of the best experts on this subject based on the ideXlab platform.

  • Managing hypertension in diabetic patients – focus on Trandolapril/Verapamil combination
    Vascular health and risk management, 2007
    Co-Authors: Sanjib Kumar Sharma, Piero Ruggenenti, Giuseppe Remuzzi
    Abstract:

    Hypertensive diabetes individuals are at higher risk for cardiovascular events and progression to end stage renal disease. Several well conducted clinical trials indicate that aggressive treatment of hypertension in individual with diabetes reduces these complications. Combinations of two or more antihypertensive drugs are frequently required to reach the target blood pressure and to improve the cardiovascular and renal outcomes in these patients. There are physiological and clinical rationales for renin-angiotensin system blockade in hypertensive diabetics. Trandolapril/Verapamil sustained released (SR) is a fixed-dose combination of Trandolapril and a sustained release formulation of Verapamil and indicated in treatment of hypertension in patients who require more than one drug to reach target blood pressure. The antihypertensive efficacy of Trandolapril/Verapamil SR has been evaluated extensively in large trials. In the INVEST trial, a Verapamil SR-based treatment strategy that included Trandolapril in most patients was effective in reducing the primary outcome in hypertensive patients with coronary artery disease. The new onset of diabetes was also significantly lower in the Verapamil SR/Trandolapril treatment group in comparison with those on the atenolol/hydroclorothiazide treatment group. The BErgamo NEphrologic Diabetes Complications Trial (BENEDICT) documented that in hypertensive diabetes and normoalbuminuria, Trandolapril Plus Verapamil or Trandolapril alone delayed the onset of microalbuminuria independent of their blood pressure-reducing effect. Thus, Trandolapril/Verapamil is an effective option for treatment of hypertensive diabetes patients requiring more than one agent to achieve target blood pressure.

  • managing hypertension in diabetic patients focus on Trandolapril Verapamil combination
    Vascular Health and Risk Management, 2007
    Co-Authors: Sanjib Kumar Sharma, Piero Ruggenenti, Giuseppe Remuzzi
    Abstract:

    Hypertensive diabetes individuals are at higher risk for cardiovascular events and progression to end stage renal disease. Several well conducted clinical trials indicate that aggressive treatment of hypertension in individual with diabetes reduces these complications. Combinations of two or more antihypertensive drugs are frequently required to reach the target blood pressure and to improve the cardiovascular and renal outcomes in these patients. There are physiological and clinical rationales for renin-angiotensin system blockade in hypertensive diabetics. Trandolapril/Verapamil sustained released (SR) is a fixed-dose combination of Trandolapril and a sustained release formulation of Verapamil and indicated in treatment of hypertension in patients who require more than one drug to reach target blood pressure. The antihypertensive efficacy of Trandolapril/Verapamil SR has been evaluated extensively in large trials. In the INVEST trial, a Verapamil SR-based treatment strategy that included Trandolapril in most patients was effective in reducing the primary outcome in hypertensive patients with coronary artery disease. The new onset of diabetes was also significantly lower in the Verapamil SR/Trandolapril treatment group in comparison with those on the atenolol/hydroclorothiazide treatment group. The BErgamo NEphrologic Diabetes Complications Trial (BENEDICT) documented that in hypertensive diabetes and normoalbuminuria, Trandolapril Plus Verapamil or Trandolapril alone delayed the onset of microalbuminuria independent of their blood pressure-reducing effect. Thus, Trandolapril/Verapamil is an effective option for treatment of hypertensive diabetes patients requiring more than one agent to achieve target blood pressure.

  • Managing hypertension in diabetic patients – focus on Trandolapril/Verapamil combination
    Dove Medical Press, 2007
    Co-Authors: Sanjib Kumar Sharma, Piero Ruggenenti, Giuseppe Remuzzi
    Abstract:

    Sanjib Kumar Sharma1,3, Piero Ruggenenti1,2, Giuseppe Remuzzi1,2, 1Clinical Research Centre for Rare Diseases “Aldo e Cele Daccò”, Mario Negri Institute for Pharmacological Research, Villa Camozzi, Ranica, Italy; 2Unit of Nephrology, Azienda Ospedaliera, Ospedali Riuniti, Bergamo, Italy; 3Department of Medicine, BP Koirala Institute of Health Sciences, Dharan, NepalAbstract: Hypertensive diabetes individuals are at higher risk for cardiovascular events and progression to end stage renal disease. Several well conducted clinical trials indicate that aggressive treatment of hypertension in individual with diabetes reduces these complications. Combinations of two or more antihypertensive drugs are frequently required to reach the target blood pressure and to improve the cardiovascular and renal outcomes in these patients. There are physiological and clinical rationales for renin-angiotensin system blockade in hypertensive diabetics. Trandolapril/Verapamil sustained released (SR) is a fixed-dose combination of Trandolapril and a sustained release formulation of Verapamil and indicated in treatment of hypertension in patients who require more than one drug to reach target blood pressure. The antihypertensive efficacy of Trandolapril/Verapamil SR has been evaluated extensively in large trials. In the INVEST trial, a Verapamil SR-based treatment strategy that included Trandolapril in most patients was effective in reducing the primary outcome in hypertensive patients with coronary artery disease. The new onset of diabetes was also significantly lower in the Verapamil SR/Trandolapril treatment group in comparison with those on the atenolol/hydroclorothiazide treatment group. The BErgamo NEphrologic DIabetes Complications Trial (BENEDICT) documented that in hypertensive diabetes and normoalbuminuria, Trandolapril Plus Verapamil or Trandolapril alone delayed the onset of microalbuminuria independent of their blood pressurereducing effect. Thus, Trandolapril/Verapamil is an effective option for treatment of hypertensive diabetes patients requiring more than one agent to achieve target blood pressure.Keywords: diabetes mellitus, hypertension, Trandolapril, Verapamil S

  • Prevention and Treatment of Diabetic Renal Disease in Type 2 Diabetes: The BENEDICT Study
    Journal of the American Society of Nephrology : JASN, 2006
    Co-Authors: Giuseppe Remuzzi, Macía M, Piero Ruggenenti
    Abstract:

    Diabetic nephropathy (DN) is the leading cause of end-stage renal failure in Western countries and carries an increased risk for cardiovascular mortality. Studies have identified a number of factors that play a part in the development of DN. Among them, hypertension and proteinuria are the most important. In the early stages of DN, when albumin is present in the urine in very low quantities (microalbuminuria) and an increase is seen in BP, there is no loss of filtrate and patients respond well to prophylactic measures. Microalbuminuria is considered an early marker of DN. Prevention of the onset of microalbuminuria, therefore, could be considered as the primary means of preventing DN. The Bergamo Nephrologic Diabetes Complication Trial (BENEDICT) was a prospective, randomized, double-blind, parallel-group study that was organized in two phases. Phase A included 1204 patients and was aimed at assessing the efficacy of the angiotensin-converting enzyme (ACE) inhibitor Trandolapril, the non-dihydropyridine calcium channel blocker Verapamil, and the Trandolapril Plus Verapamil combination as compared with placebo in prevention of microalbuminuria in hypertensive patients with type 2 diabetes and normal urinary albumin excretion rate. Phase B was aimed at assessing the efficacy of the combination as compared with Trandolapril alone in prevention of macroalbuminuria in patients with microalbuminuria. The BENEDICT Phase A study showed that DN can be prevented by ACE inhibitor therapy. The beneficial effect of ACE inhibition is not enhanced by combined non-dihydropyridine calcium channel blocker therapy. The apparent advantage of ACE inhibitors over other agents includes a protective effect on the kidney against the development of microalbuminuria, which is a major risk factor for cardiovascular events and death in this population.

  • Preventing microalbuminuria in type 2 diabetes.
    The New England journal of medicine, 2004
    Co-Authors: Piero Ruggenenti, Anna Fassi, Anelja Parvanova Ilieva, Simona Bruno, Ilian Iliev, Varusca Brusegan, Nadia Rubis, Giulia Gherardi, Federica Arnoldi, Maria Ganeva
    Abstract:

    Background The multicenter double-blind, randomized Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) was designed to assess whether angiotensin-converting–enzyme inhibitors and non-dihydropyridine calcium-channel blockers, alone or in combination, prevent microalbuminuria in subjects with hypertension, type 2 diabetes mellitus, and normal urinary albumin excretion. Methods We studied 1204 subjects, who were randomly assigned to receive at least three years of treatment with Trandolapril (at a dose of 2 mg per day) Plus Verapamil (sustained-release formulation, 180 mg per day), Trandolapril alone (2 mg per day), Verapamil alone (sustained-release formulation, 240 mg per day), or placebo. The target blood pressure was 120/80 mm Hg. The primary end point was the development of persistent microalbuminuria (overnight albumin excretion, ≥20 μg per minute at two consecutive visits). Results The primary outcome was reached in 5.7 percent of the subjects receiving Trandolapril Plus Verapamil, 6.0 percen...

Giuseppe Remuzzi - One of the best experts on this subject based on the ideXlab platform.

  • managing hypertension in diabetic patients focus on Trandolapril Verapamil combination
    Vascular Health and Risk Management, 2007
    Co-Authors: Sanjib Kumar Sharma, Piero Ruggenenti, Giuseppe Remuzzi
    Abstract:

    Hypertensive diabetes individuals are at higher risk for cardiovascular events and progression to end stage renal disease. Several well conducted clinical trials indicate that aggressive treatment of hypertension in individual with diabetes reduces these complications. Combinations of two or more antihypertensive drugs are frequently required to reach the target blood pressure and to improve the cardiovascular and renal outcomes in these patients. There are physiological and clinical rationales for renin-angiotensin system blockade in hypertensive diabetics. Trandolapril/Verapamil sustained released (SR) is a fixed-dose combination of Trandolapril and a sustained release formulation of Verapamil and indicated in treatment of hypertension in patients who require more than one drug to reach target blood pressure. The antihypertensive efficacy of Trandolapril/Verapamil SR has been evaluated extensively in large trials. In the INVEST trial, a Verapamil SR-based treatment strategy that included Trandolapril in most patients was effective in reducing the primary outcome in hypertensive patients with coronary artery disease. The new onset of diabetes was also significantly lower in the Verapamil SR/Trandolapril treatment group in comparison with those on the atenolol/hydroclorothiazide treatment group. The BErgamo NEphrologic Diabetes Complications Trial (BENEDICT) documented that in hypertensive diabetes and normoalbuminuria, Trandolapril Plus Verapamil or Trandolapril alone delayed the onset of microalbuminuria independent of their blood pressure-reducing effect. Thus, Trandolapril/Verapamil is an effective option for treatment of hypertensive diabetes patients requiring more than one agent to achieve target blood pressure.

  • Managing hypertension in diabetic patients – focus on Trandolapril/Verapamil combination
    Vascular health and risk management, 2007
    Co-Authors: Sanjib Kumar Sharma, Piero Ruggenenti, Giuseppe Remuzzi
    Abstract:

    Hypertensive diabetes individuals are at higher risk for cardiovascular events and progression to end stage renal disease. Several well conducted clinical trials indicate that aggressive treatment of hypertension in individual with diabetes reduces these complications. Combinations of two or more antihypertensive drugs are frequently required to reach the target blood pressure and to improve the cardiovascular and renal outcomes in these patients. There are physiological and clinical rationales for renin-angiotensin system blockade in hypertensive diabetics. Trandolapril/Verapamil sustained released (SR) is a fixed-dose combination of Trandolapril and a sustained release formulation of Verapamil and indicated in treatment of hypertension in patients who require more than one drug to reach target blood pressure. The antihypertensive efficacy of Trandolapril/Verapamil SR has been evaluated extensively in large trials. In the INVEST trial, a Verapamil SR-based treatment strategy that included Trandolapril in most patients was effective in reducing the primary outcome in hypertensive patients with coronary artery disease. The new onset of diabetes was also significantly lower in the Verapamil SR/Trandolapril treatment group in comparison with those on the atenolol/hydroclorothiazide treatment group. The BErgamo NEphrologic Diabetes Complications Trial (BENEDICT) documented that in hypertensive diabetes and normoalbuminuria, Trandolapril Plus Verapamil or Trandolapril alone delayed the onset of microalbuminuria independent of their blood pressure-reducing effect. Thus, Trandolapril/Verapamil is an effective option for treatment of hypertensive diabetes patients requiring more than one agent to achieve target blood pressure.

  • Managing hypertension in diabetic patients – focus on Trandolapril/Verapamil combination
    Dove Medical Press, 2007
    Co-Authors: Sanjib Kumar Sharma, Piero Ruggenenti, Giuseppe Remuzzi
    Abstract:

    Sanjib Kumar Sharma1,3, Piero Ruggenenti1,2, Giuseppe Remuzzi1,2, 1Clinical Research Centre for Rare Diseases “Aldo e Cele Daccò”, Mario Negri Institute for Pharmacological Research, Villa Camozzi, Ranica, Italy; 2Unit of Nephrology, Azienda Ospedaliera, Ospedali Riuniti, Bergamo, Italy; 3Department of Medicine, BP Koirala Institute of Health Sciences, Dharan, NepalAbstract: Hypertensive diabetes individuals are at higher risk for cardiovascular events and progression to end stage renal disease. Several well conducted clinical trials indicate that aggressive treatment of hypertension in individual with diabetes reduces these complications. Combinations of two or more antihypertensive drugs are frequently required to reach the target blood pressure and to improve the cardiovascular and renal outcomes in these patients. There are physiological and clinical rationales for renin-angiotensin system blockade in hypertensive diabetics. Trandolapril/Verapamil sustained released (SR) is a fixed-dose combination of Trandolapril and a sustained release formulation of Verapamil and indicated in treatment of hypertension in patients who require more than one drug to reach target blood pressure. The antihypertensive efficacy of Trandolapril/Verapamil SR has been evaluated extensively in large trials. In the INVEST trial, a Verapamil SR-based treatment strategy that included Trandolapril in most patients was effective in reducing the primary outcome in hypertensive patients with coronary artery disease. The new onset of diabetes was also significantly lower in the Verapamil SR/Trandolapril treatment group in comparison with those on the atenolol/hydroclorothiazide treatment group. The BErgamo NEphrologic DIabetes Complications Trial (BENEDICT) documented that in hypertensive diabetes and normoalbuminuria, Trandolapril Plus Verapamil or Trandolapril alone delayed the onset of microalbuminuria independent of their blood pressurereducing effect. Thus, Trandolapril/Verapamil is an effective option for treatment of hypertensive diabetes patients requiring more than one agent to achieve target blood pressure.Keywords: diabetes mellitus, hypertension, Trandolapril, Verapamil S

  • Prevention and Treatment of Diabetic Renal Disease in Type 2 Diabetes: The BENEDICT Study
    Journal of the American Society of Nephrology : JASN, 2006
    Co-Authors: Giuseppe Remuzzi, Macía M, Piero Ruggenenti
    Abstract:

    Diabetic nephropathy (DN) is the leading cause of end-stage renal failure in Western countries and carries an increased risk for cardiovascular mortality. Studies have identified a number of factors that play a part in the development of DN. Among them, hypertension and proteinuria are the most important. In the early stages of DN, when albumin is present in the urine in very low quantities (microalbuminuria) and an increase is seen in BP, there is no loss of filtrate and patients respond well to prophylactic measures. Microalbuminuria is considered an early marker of DN. Prevention of the onset of microalbuminuria, therefore, could be considered as the primary means of preventing DN. The Bergamo Nephrologic Diabetes Complication Trial (BENEDICT) was a prospective, randomized, double-blind, parallel-group study that was organized in two phases. Phase A included 1204 patients and was aimed at assessing the efficacy of the angiotensin-converting enzyme (ACE) inhibitor Trandolapril, the non-dihydropyridine calcium channel blocker Verapamil, and the Trandolapril Plus Verapamil combination as compared with placebo in prevention of microalbuminuria in hypertensive patients with type 2 diabetes and normal urinary albumin excretion rate. Phase B was aimed at assessing the efficacy of the combination as compared with Trandolapril alone in prevention of macroalbuminuria in patients with microalbuminuria. The BENEDICT Phase A study showed that DN can be prevented by ACE inhibitor therapy. The beneficial effect of ACE inhibition is not enhanced by combined non-dihydropyridine calcium channel blocker therapy. The apparent advantage of ACE inhibitors over other agents includes a protective effect on the kidney against the development of microalbuminuria, which is a major risk factor for cardiovascular events and death in this population.

Sanjib Kumar Sharma - One of the best experts on this subject based on the ideXlab platform.

  • managing hypertension in diabetic patients focus on Trandolapril Verapamil combination
    Vascular Health and Risk Management, 2007
    Co-Authors: Sanjib Kumar Sharma, Piero Ruggenenti, Giuseppe Remuzzi
    Abstract:

    Hypertensive diabetes individuals are at higher risk for cardiovascular events and progression to end stage renal disease. Several well conducted clinical trials indicate that aggressive treatment of hypertension in individual with diabetes reduces these complications. Combinations of two or more antihypertensive drugs are frequently required to reach the target blood pressure and to improve the cardiovascular and renal outcomes in these patients. There are physiological and clinical rationales for renin-angiotensin system blockade in hypertensive diabetics. Trandolapril/Verapamil sustained released (SR) is a fixed-dose combination of Trandolapril and a sustained release formulation of Verapamil and indicated in treatment of hypertension in patients who require more than one drug to reach target blood pressure. The antihypertensive efficacy of Trandolapril/Verapamil SR has been evaluated extensively in large trials. In the INVEST trial, a Verapamil SR-based treatment strategy that included Trandolapril in most patients was effective in reducing the primary outcome in hypertensive patients with coronary artery disease. The new onset of diabetes was also significantly lower in the Verapamil SR/Trandolapril treatment group in comparison with those on the atenolol/hydroclorothiazide treatment group. The BErgamo NEphrologic Diabetes Complications Trial (BENEDICT) documented that in hypertensive diabetes and normoalbuminuria, Trandolapril Plus Verapamil or Trandolapril alone delayed the onset of microalbuminuria independent of their blood pressure-reducing effect. Thus, Trandolapril/Verapamil is an effective option for treatment of hypertensive diabetes patients requiring more than one agent to achieve target blood pressure.

  • Managing hypertension in diabetic patients – focus on Trandolapril/Verapamil combination
    Vascular health and risk management, 2007
    Co-Authors: Sanjib Kumar Sharma, Piero Ruggenenti, Giuseppe Remuzzi
    Abstract:

    Hypertensive diabetes individuals are at higher risk for cardiovascular events and progression to end stage renal disease. Several well conducted clinical trials indicate that aggressive treatment of hypertension in individual with diabetes reduces these complications. Combinations of two or more antihypertensive drugs are frequently required to reach the target blood pressure and to improve the cardiovascular and renal outcomes in these patients. There are physiological and clinical rationales for renin-angiotensin system blockade in hypertensive diabetics. Trandolapril/Verapamil sustained released (SR) is a fixed-dose combination of Trandolapril and a sustained release formulation of Verapamil and indicated in treatment of hypertension in patients who require more than one drug to reach target blood pressure. The antihypertensive efficacy of Trandolapril/Verapamil SR has been evaluated extensively in large trials. In the INVEST trial, a Verapamil SR-based treatment strategy that included Trandolapril in most patients was effective in reducing the primary outcome in hypertensive patients with coronary artery disease. The new onset of diabetes was also significantly lower in the Verapamil SR/Trandolapril treatment group in comparison with those on the atenolol/hydroclorothiazide treatment group. The BErgamo NEphrologic Diabetes Complications Trial (BENEDICT) documented that in hypertensive diabetes and normoalbuminuria, Trandolapril Plus Verapamil or Trandolapril alone delayed the onset of microalbuminuria independent of their blood pressure-reducing effect. Thus, Trandolapril/Verapamil is an effective option for treatment of hypertensive diabetes patients requiring more than one agent to achieve target blood pressure.

  • Managing hypertension in diabetic patients – focus on Trandolapril/Verapamil combination
    Dove Medical Press, 2007
    Co-Authors: Sanjib Kumar Sharma, Piero Ruggenenti, Giuseppe Remuzzi
    Abstract:

    Sanjib Kumar Sharma1,3, Piero Ruggenenti1,2, Giuseppe Remuzzi1,2, 1Clinical Research Centre for Rare Diseases “Aldo e Cele Daccò”, Mario Negri Institute for Pharmacological Research, Villa Camozzi, Ranica, Italy; 2Unit of Nephrology, Azienda Ospedaliera, Ospedali Riuniti, Bergamo, Italy; 3Department of Medicine, BP Koirala Institute of Health Sciences, Dharan, NepalAbstract: Hypertensive diabetes individuals are at higher risk for cardiovascular events and progression to end stage renal disease. Several well conducted clinical trials indicate that aggressive treatment of hypertension in individual with diabetes reduces these complications. Combinations of two or more antihypertensive drugs are frequently required to reach the target blood pressure and to improve the cardiovascular and renal outcomes in these patients. There are physiological and clinical rationales for renin-angiotensin system blockade in hypertensive diabetics. Trandolapril/Verapamil sustained released (SR) is a fixed-dose combination of Trandolapril and a sustained release formulation of Verapamil and indicated in treatment of hypertension in patients who require more than one drug to reach target blood pressure. The antihypertensive efficacy of Trandolapril/Verapamil SR has been evaluated extensively in large trials. In the INVEST trial, a Verapamil SR-based treatment strategy that included Trandolapril in most patients was effective in reducing the primary outcome in hypertensive patients with coronary artery disease. The new onset of diabetes was also significantly lower in the Verapamil SR/Trandolapril treatment group in comparison with those on the atenolol/hydroclorothiazide treatment group. The BErgamo NEphrologic DIabetes Complications Trial (BENEDICT) documented that in hypertensive diabetes and normoalbuminuria, Trandolapril Plus Verapamil or Trandolapril alone delayed the onset of microalbuminuria independent of their blood pressurereducing effect. Thus, Trandolapril/Verapamil is an effective option for treatment of hypertensive diabetes patients requiring more than one agent to achieve target blood pressure.Keywords: diabetes mellitus, hypertension, Trandolapril, Verapamil S

Maria Ganeva - One of the best experts on this subject based on the ideXlab platform.

  • Preventing microalbuminuria in type 2 diabetes.
    The New England journal of medicine, 2004
    Co-Authors: Piero Ruggenenti, Anna Fassi, Anelja Parvanova Ilieva, Simona Bruno, Ilian Iliev, Varusca Brusegan, Nadia Rubis, Giulia Gherardi, Federica Arnoldi, Maria Ganeva
    Abstract:

    Background The multicenter double-blind, randomized Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) was designed to assess whether angiotensin-converting–enzyme inhibitors and non-dihydropyridine calcium-channel blockers, alone or in combination, prevent microalbuminuria in subjects with hypertension, type 2 diabetes mellitus, and normal urinary albumin excretion. Methods We studied 1204 subjects, who were randomly assigned to receive at least three years of treatment with Trandolapril (at a dose of 2 mg per day) Plus Verapamil (sustained-release formulation, 180 mg per day), Trandolapril alone (2 mg per day), Verapamil alone (sustained-release formulation, 240 mg per day), or placebo. The target blood pressure was 120/80 mm Hg. The primary end point was the development of persistent microalbuminuria (overnight albumin excretion, ≥20 μg per minute at two consecutive visits). Results The primary outcome was reached in 5.7 percent of the subjects receiving Trandolapril Plus Verapamil, 6.0 percen...

Pm Vanhoutte - One of the best experts on this subject based on the ideXlab platform.

  • Trandolapril Plus Verapamil inhibits the coronary vasospasm induced by hypoxia following ischemia-reperfusion injury in dogs
    'Elsevier BV', 1996
    Co-Authors: Jj Lee, Cm Boulanger, Kirchengast M, Pm Vanhoutte
    Abstract:

    Dogs were exposed to hypoxemia followed by a coronary angiogram at three different times: under control conditions, after ischemia-reperfusion injury, then 30 min later. In the study group, the dogs were treated with Trandolapril (0.05 mg/kg) and Verapamil (0.1 mg/kg) just prior to the final hypoxic challenge. Under control conditions, the left anterior descending coronary artery (LAD) dilated in response to hypoxia. Following ischemia-reperfusion injury, however, it constricted significantly in response. In the control group, repeat hypoxia 30 min later resulted in vasoconstriction of the LAD which was comparable to the preceding response. However, in the study group, treatment with Trandolapril Plus Verapamil inhibited the vasoconstriction in response to repeat hypoxia.link_to_subscribed_fulltex